Clinical Trials Directory

Trials / Completed

CompletedNCT03310229

Pulmonary Hypertension in Haemodialysis Patients :Frequency and Risk Factors

Status
Completed
Phase
Study type
Observational
Enrollment
80 (actual)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

High mortality rates due to cardiovascular disease in end-stage renal disease patients been described by epidemiological and clinical studies. It accounts for approximately 50 percent of deaths in dialysis patients. Although controversial, this may be due to the presence of excess vascular calcification particularly in the form of extensive coronary artery calcification which can be observed even in very young dialysis patients. It was suggested that abnormalities of the right ventricular function in patients with end-stage renal disease were largely due to pulmonary hypertension which usually develops secondary to pulmonary artery calcifications.

Detailed description

Primary whose mechanisms are incompletely known, is another vascular disease entity recently described in chronic kidney disease particularly in patients undergoing haemodialysis. It corresponds to 5th subtype of World Symposium on Pulmonary Hypertension classification established in 2008 in Dana Point and updated in 2013 in Nice. Pulmonary hypertension is defined by Pulmonary arterial pressure mean ≥25 mm Hg at rest measured by right heart catheterization. Its pathophysiological mechanism is controversy maybe explained by vascular calcification, blood flow in arteriovenous fistula and fluid overload. Primary pulmonary hypertension is a major problem of haemodialysis patients because of its high prevalence, sometimes reaching 68% and by its significant morbidity and mortality.

Conditions

Interventions

TypeNameDescription
RADIATIONplain chest x-raythe participants will be subjected to plain chest x-ray with other tools to help diagnose pulmonary hypertension in haemodialysis patients

Timeline

Start date
2018-12-01
Primary completion
2019-12-01
Completion
2019-12-02
First posted
2017-10-16
Last updated
2021-01-20

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT03310229. Inclusion in this directory is not an endorsement.